Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBN4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,747
Award facts
- Contract value 100% obligated
- $30,747.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $30.7K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL 266 mg/20 mL vials. The award was issued on November 26, 2025, with an ultimate completion date of December 18, 2025. EXPAREL is a specialty surgical anesthetic product used in pain management during medical procedures. This delivery order carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9B acquisition strategy establishing multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the Defense Logistics Agency's Medical Supply Chain division, with recent delivery orders spanning branded and generic prescription medications, biologics, vaccines, specialty surgical products, and medical consumables. The company's established performance on numerous pharmaceutical supply orders positions it to fulfill the diverse and specialized requirements of military healthcare operations globally. The PPV-G GEN V contract structure, which commenced on November 13, 2025, with a base period and three optional 30-month renewal periods extending through December 31, 2036, enables the Defense Logistics Agency to issue firm fixed-price delivery orders efficiently to support recurring medical supply needs across the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FFBN4?
SPE2DR26FFBN4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 26, 2025.
How much is contract SPE2DR26FFBN4 worth?
The government has obligated $30,747 on SPE2DR26FFBN4.
Is contract SPE2DR26FFBN4 an order under another contract?
Yes. SPE2DR26FFBN4 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBN4 competed?
The extent of competition for SPE2DR26FFBN4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award